-
Je něco špatně v tomto záznamu ?
Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer
K. Liu, R. Nicoletti, H. Zhao, X. Chen, H. Wu, CH. Leung, D. D'Andrea, E. Laukhtina, F. Soria, A. Gallioli, ML. Wroclawski, D. Castellani, V. Gauhar, JG. Rivas, D. Enikeev, P. Gontero, SF. Shariat, PK. Chiu, CF. Ng, JY. Teoh
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
Grantová podpora
8601521
UGC Research Matching Fund
14117421
General Research Fund and Early Career Scheme
NLK
ProQuest Central
od 1997-02-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-02-01 do Před 1 rokem
- MeSH
- adjuvancia imunologická * terapeutické užití MeSH
- aplikace intravezikální MeSH
- BCG vakcína * terapeutické užití MeSH
- invazivní růst nádoru * MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- nádory močového měchýře neinvadující svalovinu MeSH
- nádory močového měchýře * farmakoterapie patologie terapie mortalita MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- věkové faktory MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVE: To investigate the impact of ageing on survival outcomes in Bacillus Calmette-Guérin (BCG) treated non-muscle invasive bladder cancer (NMIBC) patients and its synergy with adequate BCG treatment. METHOD: Patients with NMIBC who received BCG treatment from 2001 to 2020 were divided into group 1 (< = 70 years) and group 2 (> 70 years). Overall Survival (OS), Cancer-Specific Survival (CSS), Recurrence-Free Survival (RFS), and Progression-Free Survival (PFS) were analyzed using the Kaplan-Meier method. Multivariable Cox regression analysis was used to adjust potential confounding factors and to estimate Hazard Ratio (HR) and 95% Confidence Interval (CI). Subgroup analysis was performed according to adequate versus inadequate BCG treatment. RESULTS: Overall, 2602 NMIBC patients were included: 1051 (40.4%) and 1551 (59.6%) in groups 1 and 2, respectively. At median follow-up of 11.0 years, group 1 (< = 70 years) was associated with better OS, CSS, and RFS, but not PFS as compared to group 2 (> 70 years). At subgroup analysis, patients in group 1 treated with adequate BCG showed better OS, CSS, RFS, and PFS as compared with inadequate BCG treatment in group 2, while patients in group 2 receiving adequate BCG treatment had 41% less progression than those treated with inadequate BCG from the same group. CONCLUSIONS: Being younger (< = 70 years) was associated with better OS, CSS, and RFS, but not PFS. Older patients (> 70 years) who received adequate BCG treatment had similar PFS as those younger with adequate BCG treatment.
Cancer Prognostics and Health Outcomes Unit University of Montreal Health Centre Montreal Canada
Department of Experimental and Clinical Biomedical Science University of Florence Florence Italy
Department of Urology Clinico San Carlos University Hospital Madrid Spain
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology Faculdade de Medicina Do ABC Santo André Brazil
Department of Urology Fundació Puigvert Autonoma University of Barcelona Barcelona Spain
Department of Urology Hospital Beneficencia Portuguesa de Sao Paulo São Paulo Brazil
Department of Urology Hospital Israelita Albert Einstein São Paulo Brazil
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Urology Rabin Medical Center Petah Tikva Israel
Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018853
- 003
- CZ-PrNML
- 005
- 20241024111113.0
- 007
- ta
- 008
- 241015s2024 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00345-024-05218-4 $2 doi
- 035 __
- $a (PubMed)39331198
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Liu, Kang $u S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong
- 245 10
- $a Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer / $c K. Liu, R. Nicoletti, H. Zhao, X. Chen, H. Wu, CH. Leung, D. D'Andrea, E. Laukhtina, F. Soria, A. Gallioli, ML. Wroclawski, D. Castellani, V. Gauhar, JG. Rivas, D. Enikeev, P. Gontero, SF. Shariat, PK. Chiu, CF. Ng, JY. Teoh
- 520 9_
- $a OBJECTIVE: To investigate the impact of ageing on survival outcomes in Bacillus Calmette-Guérin (BCG) treated non-muscle invasive bladder cancer (NMIBC) patients and its synergy with adequate BCG treatment. METHOD: Patients with NMIBC who received BCG treatment from 2001 to 2020 were divided into group 1 (< = 70 years) and group 2 (> 70 years). Overall Survival (OS), Cancer-Specific Survival (CSS), Recurrence-Free Survival (RFS), and Progression-Free Survival (PFS) were analyzed using the Kaplan-Meier method. Multivariable Cox regression analysis was used to adjust potential confounding factors and to estimate Hazard Ratio (HR) and 95% Confidence Interval (CI). Subgroup analysis was performed according to adequate versus inadequate BCG treatment. RESULTS: Overall, 2602 NMIBC patients were included: 1051 (40.4%) and 1551 (59.6%) in groups 1 and 2, respectively. At median follow-up of 11.0 years, group 1 (< = 70 years) was associated with better OS, CSS, and RFS, but not PFS as compared to group 2 (> 70 years). At subgroup analysis, patients in group 1 treated with adequate BCG showed better OS, CSS, RFS, and PFS as compared with inadequate BCG treatment in group 2, while patients in group 2 receiving adequate BCG treatment had 41% less progression than those treated with inadequate BCG from the same group. CONCLUSIONS: Being younger (< = 70 years) was associated with better OS, CSS, and RFS, but not PFS. Older patients (> 70 years) who received adequate BCG treatment had similar PFS as those younger with adequate BCG treatment.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory močového měchýře $x farmakoterapie $x patologie $x terapie $x mortalita $7 D001749
- 650 12
- $a BCG vakcína $x terapeutické užití $7 D001500
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a invazivní růst nádoru $7 D009361
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a adjuvancia imunologická $x terapeutické užití $7 D000276
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a aplikace intravezikální $7 D000283
- 650 _2
- $a nádory močového měchýře neinvadující svalovinu $7 D000093284
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Nicoletti, Rossella $u S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong $u Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy
- 700 1_
- $a Zhao, Hongda $u S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong
- 700 1_
- $a Chen, Xuan $u S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong
- 700 1_
- $a Wu, Hongwei $u S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong
- 700 1_
- $a Leung, Chi-Ho $u S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong
- 700 1_
- $a D'Andrea, David $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Urothelial Cancer Working Group, European Association of Urology-Young Academic Urologists (EAU-YAU), Amsterdam, Netherlands
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Soria, Francesco $u Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, 10024, Turin, Italy
- 700 1_
- $a Gallioli, Andrea $u Urothelial Cancer Working Group, European Association of Urology-Young Academic Urologists (EAU-YAU), Amsterdam, Netherlands $u Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain
- 700 1_
- $a Wroclawski, Marcelo Langer $u Department of Urology, Hospital Israelita Albert Einstein, São Paulo, Brazil $u Department of Urology, Hospital Beneficencia Portuguesa de Sao Paulo, São Paulo, Brazil $u Department of Urology, Faculdade de Medicina Do ABC, Santo André, Brazil
- 700 1_
- $a Castellani, Daniele $u Urology Unit, Azienda Ospedaliero-Universitaria Delle Marche, Università Politecnica Delle Marche, Ancona, Italy
- 700 1_
- $a Gauhar, Vineet $u Department of Urology, Ng Teng Fong General Hospital, National University Health System, Singapore, Singapore
- 700 1_
- $a Rivas, Juan Gomez $u Department of Urology, Clinico San Carlos University Hospital, Madrid, Spain
- 700 1_
- $a Enikeev, Dmitry $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Division of Urology, Rabin Medical Center, Petah Tikva, Israel
- 700 1_
- $a Gontero, Paolo $u Department of Urology, Città Della Salute E Della Scienza, University of Torino School of Medicine, Turin, Italy
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u 2nd Faculty of Medicine, Hospital Motol, Department of Urology, Charles University, Prague, Czech Republic $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada $u Research Center for Evidence-Based Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran
- 700 1_
- $a Chiu, Peter Ka-Fung $u S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong
- 700 1_
- $a Ng, Chi-Fai $u S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. ngcf@surgery.cuhk.edu.hk
- 700 1_
- $a Teoh, Jeremy Yuen-Chun $u S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. jeremyteoh@surgery.cuhk.edu.hk $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. jeremyteoh@surgery.cuhk.edu.hk $u Urothelial Cancer Working Group, European Association of Urology-Young Academic Urologists (EAU-YAU), Amsterdam, Netherlands. jeremyteoh@surgery.cuhk.edu.hk
- 773 0_
- $w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 42, č. 1 (2024), s. 547
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39331198 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111107 $b ABA008
- 999 __
- $a ok $b bmc $g 2201613 $s 1230826
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 42 $c 1 $d 547 $e 20240927 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
- GRA __
- $a 8601521 $p UGC Research Matching Fund
- GRA __
- $a 14117421 $p General Research Fund and Early Career Scheme
- LZP __
- $a Pubmed-20241015
